Mode
Text Size
Log in / Sign up
Phase 3 N=523 Randomized Treatment

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Postoperative Atrial Fibrillation

Enrolled (actual)
523
Serious AEs
27.5%
Results posted
Jan 2017
Primary outcome: Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Amiodarone (Drug); DC-cardioversion (Procedure); Rate Control (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Icahn School of Medicine at Mount Sinai
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Number of Days in Hospital
5.1; 5.0 0.76
SECONDARY
Time to Conversion to Sustained, Stable Non-AF Rhythm
1.85; 0.95 0.003 sig
SECONDARY
Heart Rhythm Comparison
220; 231 0.03 sig
SECONDARY
Heart Rhythm Comparison
220; 231 0.03 sig
SECONDARY
Heart Rhythm Comparison
220; 231 0.03 sig
SECONDARY
Length of Stay (Index Hospitalization)
4.3; 4.3 0.88
SECONDARY
Length of Stay (Rehospitalization, Including ED Visits)
2.2; 2.1 0.82
SECONDARY
Outpatient Interventions
5; 4 0.73
SECONDARY
AF- or Treatment-related Events
SECONDARY
Cost (Hospital)

Summary

The purpose of this study is to compare the therapeutic strategies of rate control versus rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial fibrillation or atrial flutter (AF). In patients who develop AF during hospitalization after cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days in hospital within 60 days of the occurrence of AF compared to a strategy of rate control.

Eligibility Criteria

Enrollment Inclusion Criteria:

  • Age > 18 years
  • Undergoing heart surgery for coronary artery bypass (on-pump or off-pump CABG) and/or valve repair or replacement (excluding mechanical valves), including re-operations
  • Hemodynamically stable

Randomization Inclusion Criteria

  • AF that persists for > 60 minutes or recurrent (more than one) episodes of AF up to 7 days after surgery during the index hospitalization.

Exclusion Criteria

  • LVAD insertion or heart transplantation
  • Maze procedure
  • TAVR
  • History of or planned mechanical valve replacement
  • Correction of complex congenital cardiac defect (excluding bicuspid aortic valve, atrial septal defect or PFO)
  • History of AF or AFL
  • History of AF or AFL ablation
  • Contraindications to warfarin or amiodarone
  • Need for long-term anticoagulation
  • Concurrent participation in an interventional (drug or device) trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02132767). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search